KalVista announced that Benjamin Palleiko, the company’s current President, CBO and CFO, has been appointed as CEO and a director of the company, effective immediately. In conjunction, Andrew Crockett has submitted his resignation as CEO and a director of the company. This appointment is the result of a planned transition as KalVista prepares to become a commercial entity following the success of the Konfident Phase 3 trial for its program sebetralstat as the first potential oral, on-demand therapy for hereditary angioedema, with a planned US NDA filing in the first half of this year. Ben Palleiko joined KalVista in 2016 as CFO. Prior to his business career, he served on active duty for seven years in the US Navy as a Naval Aviator flying carrier-based jet aircraft.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KALV:
- KalVista presents additional Phase 3 KONFIDENT data at AAAAI meeting
- KalVista awarded UK Innovation Passport for sebetralstat
- KalVista Pharmaceuticals Secures Funding to Advance Clinical Programs
- KalVista CFO Palleiko sells 40,855 common shares
- Biotech Alert: Searches spiking for these stocks today
Questions or Comments about the article? Write to editor@tipranks.com